Boston Scientific (BSX) Price Target Cut to $64 by Truist

AI Summary

Truist has decreased its price target for Boston Scientific Corp. (BSX) from $85 to $64 while maintaining a Buy rating. This revision comes after management indicated slowing growth in the U.S. market for the Watchman device. Goldman Sachs also cut its target price for BSX from $81 to $71, while still offering a Buy rating, noting expected revenue growth of at least 7% and a double-digit increase in EPS. The adjustments reflect analysts' concerns over the product's performance but confidence in BSX's broader financial profile.